NASDAQ$DCTH
Delcath Systems Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Delcath reported an increase in product revenue and a net loss for the second quarter of 2021.
Delcath Systems, Inc. reported an increase in product revenue for the second quarter of 2021, driven by sales of CHEMOSAT procedures in Europe. The company also announced positive efficacy results from its FOCUS Phase III trial of HEPZATO™ KIT and entered into a debt facility with Avenue Venture Opportunities Fund, L.P.
- Product revenue for Q2 2021 was $536 thousand, compared to $379 thousand for the prior year period.
- The company had positive efficacy results from its FOCUS Phase III trial of HEPZATO™ KIT.
- Delcath entered into a debt facility with Avenue Venture Opportunities Fund, L.P. providing up to $20 million.
- The company recorded a net loss of $6.4 million for the quarter, compared to a net income of $4.3 million for the same period in 2020.
Headline financials
Revenue & EPS history
Delcath · Revenue · Quarterly
$109K
Forward guidance
Delcath plans to file the HEPZATO NDA in early 2022 and prepare for the subsequent US launch, while also expanding the development of HEPZATO into additional areas of high unmet need.
Tailwinds
- Filing of the HEPZATO NDA in early 2022.
- Preparing for the subsequent US launch of HEPZATO.
- Expanding the development of HEPZATO into additional areas of high unmet need.
- New patient level data at ASCO strengthens the case for HEPZATO's clinical benefit.
- Secured additional capital from Avenue Venture Opportunities Fund.
Headwinds
- Uncertainties relating to the timing and results of clinical trials.
- Impact of the COVID-19 pandemic on the completion of clinical trials.
- Actions by the FDA or foreign regulatory agencies.
- The Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same.
- Uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-2.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+7.7%
Avg return
30 days after
28%
9 / 32 earnings
Positive
+37.5%
Q2 2019
Best reaction
-26.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +0.6% | -5.3% | |
| Q4 2025 | -11.7% | -15.8% | -12.1% | |
| Q3 2025 | -4.7% | -9.2% | +5.3% | |
| Q1 2025 | +23.6% | +31.7% | +41.1% | |
| Q4 2024 | -1.6% | -12.1% | -18.0% | |
| Q3 2024 | -9.0% | -14.0% | +8.5% | |
| Q2 2024 | -2.6% | -4.2% | +33.7% | |
| Q1 2024 | +33.1% | +40.2% | +37.4% | |
| Q4 2023 | +9.2% | +2.4% | +12.9% | |
| Q3 2023 | -23.7% | -16.9% | +10.0% | |
| Q2 2023 | -20.6% | -23.3% | +18.2% | |
| Q1 2023 | +0.2% | +7.8% | +14.9% | |
| Q4 2022 | +22.3% | +18.8% | +17.6% | |
| Q3 2022 | -6.7% | +0.0% | +11.3% | |
| Q2 2022 | -2.3% | +10.2% | -5.4% | |
| Q1 2022 | -11.9% | -16.7% | -28.1% | |
| Q4 2021 | +1.3% | +2.8% | +0.0% | |
| Q3 2021 | -1.8% | -5.0% | -28.1% | |
| Q2 2021 | -11.8% | -13.5% | +1.1% | |
| Q1 2021 | -7.0% | -0.6% | +9.8% | |
| Q4 2020 | -24.8% | -7.2% | -31.8% | |
| Q3 2020 | +0.6% | +3.6% | +36.7% | |
| Q2 2020 | -2.6% | -4.6% | -9.3% | |
| Q1 2020 | -5.2% | -5.2% | +0.5% | |
| Q4 2019 | +0.0% | +13.8% | +55.7% | |
| Q3 2019 | -4.3% | -4.3% | -15.2% | |
| Q2 2019 | +37.5% | +27.5% | +26.2% | |
| Q1 2019 | -11.2% | +0.0% | +22.5% | |
| Q4 2018 | -6.5% | -8.9% | -35.5% | |
| Q3 2018 | -26.4% | -0.3% | -5.6% | |
| Q2 2018 | +0.0% | +19.0% | +78.8% | |
| Q1 2018 | +2.4% | +0.3% | -0.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro